CXCL9, an IFN-γ inducible chemokine, has been reported to play versatile roles in tumor-host interrelationships. However, little is known about its role in intrahepatic cholangiocarcinoma (iCCA). Here, we aimed to elucidate the prognostic and biological implications of CXCL9 in iCCA. Endogenous CXCL9 expression and the number of tumor-infiltrating lymphocytes were immunohistochemically assessed in resection specimens. These data were validated in mice treated by silencing CXCL9 with short hairpin RNA. In addition, the induction of endogenous CXCL9 and the effects of CXCL9 on tumor biological behaviors were evaluated in human cholangiocarcinoma cell lines. Immunohistochemical analyses revealed that high CXCL9 expression was closely correlated with prolonged postoperative survival and a large number of tumor-infiltrating natural killer (NK) cells. In fact, due to the trafficking of total and tumor necrosis factor-related apoptosis-inducing ligand-expressing NK cells into tumors, CXCL9-sufficient cells were less tumorigenic in the liver than CXCL9-deficient cells in mice. Although CXCL9 involvement in tumor growth and invasion abilities differed across cell lines, it did not exacerbate these abilities in CXCL9-expressing cell lines. We showed that CXCL9 was useful as a prognostic marker. Our findings also suggested that CXCL9 upregulation might offer a therapeutic strategy for treating CXCL9-expressing iCCA by augmenting anti-tumor immune surveillance.
| INTRODUC TI ON
Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary hepatic malignancy that originates from intrahepatic bile epithelium. Although iCCA is a relatively infrequent entity, alarming rises in iCCA incidence and iCCA-related mortality have been reported worldwide over the past few decades. 1, 2 In addition, surgical resection and transplantation remain the only potentially curative approaches, and limited chemotherapeutic treatment options and frequent treatment resistance are unduly prominent in patients with iCCA. [3] [4] [5] [6] Hence, the iCCA prognosis continues to be pessimistic, with a 5-year survival rate of <10%, 7 and rapid, fatal deterioration.
It has become increasingly important to understand the tumor-host interrelationship to help overcome malignancies. Recent accumulated evidence has shown that the tumor immune microenvironment (TIME) intensely dictates tumor fate. Favorable cancer-immune editing can provide new therapeutic directions that might potentially eradicate tumors, exemplified by adoptive immune cell therapy 8 or immune check-point blockage. 9 However, recent studies have shown that only a small subset of patients with iCCA derive therapeutic benefits from immune-modulating drugs. 10, 11 Developing effective therapies that can alter TIME remains challenging.
Chemokines comprise a large family of small, functionally divergent molecules that play crucial roles in orchestrating TIME, tumor growth and metastases. Among the various types of chemokines, CXCL9 is a member of the ELR-motif negative-CXC chemokine family, which is induced by IFN-γ. CXCL9 is produced by macrophages, endothelial cells, hepatocytes and tumors. As a CXCR3 ligand, CXCL9 mainly acts as a chemoattractant to activated immune cells, including T cells and natural killer (NK) cells. 12 We previously reported that intra-graft CXCL9 mRNA was an effective biomarker of acute cellular rejection (ACR) after liver transplantation. 13 In this study, we showed that intra-graft CXCL9
was most upregulated in patients with ACR, and its expression was sensitive to ACR treatments, indicating that CXCL9 was a key regulator of liver cellular immunity. Gorbachev et al 14 showed that CXCL9-deficient tumor cells were more tumorigenic than CXCL9-sufficient counterparts because CXCL9-deficient tumor cells disrupted activated T-cell and NK-cell recruitment into tumors in murine cutaneous fibrosarcoma. In addition, CXCL9 directly influenced tumor biological properties by binding to the CXCR3 receptor. Importantly, there are two CXCR3 splice variants, CXCR3A and CXCR3B, with pro-tumor and anti-tumor functions, respectively.
Studies have shown that CXCR3A contributed to tumor invasion and metastases, and that CXCR3B suppressed these activities in cancer settings. [15] [16] [17] [18] Furthermore, previous studies revealed that elevated CXCL9 expression was associated with favorable survival following curative surgery in ovarian and colorectal cancers, 19, 20 whereas it was connected to unfavorable postoperative outcome in renal cell carcinoma. 21 These findings indicated that CXCL9 plays various roles, some contradictory, depending on the cancer type. Few studies have explored the prognostic and biological significance of CXCL9 in iCCA.
We hypothesized that endogenous CXCL9 expression might regulate TIME and tumor behaviors, and, thus, it might be associated with patient prognosis in iCCA. Accordingly, the present study aimed to evaluate the prognostic significance of endogenous CXCL9 expression and its impact on TIME and tumor biological behaviors in iCCA.
| MATERIAL S AND ME THODS

| Cell lines and cell culture
For in vitro experiments, we used four human CCA cell lines:
MzChA-1, TFK-1, HuCCT-1 and CCLP-1. 
| Patients and tissue samples
We analyzed tissue samples from 70 consecutive patients who underwent potentially curative resections for iCCA, between September 1998 and January 2015 at Osaka University Hospital. In all patients, iCCA was histologically confirmed by expert pathologists at our institute. Clinicopathological patient characteristics are summarized in Table S1 . In 41 patients, tumors were classified as the peripheral type, and approximately half were in stages ≤ II based on the 8th edition of the UICC TNM classification system. 26 The use of clinical samples was approved by the Human Ethics Review Committee of Osaka University Graduate School of Medicine (no. 15149). Informed consent forms were signed by each patient before participation.
| Histological analysis
Specimens were fixed with 10% formalin and embedded in paraffin. Next, 2.5-µm sections were cut, mounted on slides, and stained for immunohistochemistry (IHC) analyses. Slides were deparaffinized, and antigens were retrieved with sodium citrate buffer (pH 6) and autoclave heating. Next, slides were incubated overnight at 4°C with primary Abs specific for CXCL9, CD8, NCR1, FOXP3 and cytokeratin (CK) 19, or incubated at room temperature for 30 minutes with a primary Ab specific for T-bet. Primary Abs and dilutions were listed in Table S2 . Slides were subsequently stained with Dako DAB+ substrate buffer (Agilent) and counterstained with hematoxylin. Microscopic evaluations were conducted by two independent observers (YF and MK), who had no knowledge of clinicopathological factors in each patient.
| CXCL9 knockdown with shRNA-mediated gene silencing
MISSION shRNA, frozen in bacterial glycerol stocks, were purchased from Sigma-Aldrich. These sequence-verified shRNA lentiviral TRC2-pLKO-puro plasmids were designed to silence murine CXCL9.
In this study, we used two shRNA that targeted different sequences Subclones were obtained with the limiting dilution method. 
| Flow cytometry and other methods
| In vivo experiment
The 
| Statistical analysis
Statistical analyses were performed with JMP software (SAS Institute). Continuous variables were expressed as the median (range) or mean ± SD. Variables were compared between groups with the Student's t test, Welch's t test or Wilcoxon signed-rank test, as appropriate. Survival curves were estimated using the KaplanMeier method, and compared using the log-rank test. Univariate and multivariate analyses were carried out using a Cox proportional hazards model and any variable deemed significant (P < 0.05) in the univariate analyses could be a candidate for multivariate analyses.
P-values < 0.05 were considered significant.
| RE SULTS
| High endogenous CXCL9 expression was correlated with favorable postoperative survival
We evaluated endogenous CXCL9 expression in 70 resected specimens with IHC. CXCL9 was predominantly stained in tumor cell cy- Table S3 ).
Patients with CXCL9 high showed favorable postoperative overall survival (OS; P = 0.0035; Figure 1B ) and recurrence-free survival (RFS; P < 0.0001; Figure 1C ) compared to those with CXCL9 Table 1 ). In contrast, no significant factors were associated with overall survival (Table S4 ).
| High endogenous CXCL9 expression was associated with high numbers of tumor-infiltrating natural killer cells
Next, we analyzed the extent to which endogenous CXCL9 expres- Cell proliferation was similar across these three cell lines ( Figure   S2 ). We inoculated all three cell lines into the spleen of mice, and 35 days later, tumor-bearing mice were killed. Tumors in the liver were manually, meticulously trimmed ( Figure 3A) . Tumor volumes (% of whole liver) were significantly higher in mice inoculated with the two CXCL9-deficient cell lines compared to mice inoculated with control cells ( Figure 3B ). All tumors were strongly stained with the CK19 Ab, a marker of bile duct epithelial cells, but CXCL9 expression was higher in control tumors compared to CXCL9-deficient tumors . Isotype controls were used as negative controls to help differentiate non-specific background signal from anti-CD3, NK1.1, TRAIL and CXCR3 Abs. All data are the mean ± SD. *P < 0.05, **P < 0.01, N.S., not significant NK-cell depleted conditions. We found that the NK depletion eliminated the volume differences between CXCL9-sufficient and CXCL9-deficient tumors ( Figure 3K ).
TA B L E 1
Clinicopathological factors that potentially affect recurrence-free survival
| CXCL9 was released in response to inflammatory stimuli in cholangiocarcinoma cell lines
Our IHC and in vivo analyses indicated that increased CXCL9 expression might improve patient survival by regulating TIME. However, we also aimed to elucidate the impact of CXCL9 on tumor cell biological properties because previous studies demonstrated that CXCL9 could promote tumor growth. 16 HuCCT-1 and CCLP-1 cells ( Figure 4D ). Finally, we screened two signaling pathways, the PI3K/AKT pathway and the ERK1/2 pathway, which were reported to be activated via the CXCL9-CXCR3 axis in different cancer settings. 16, 27 Administration of 100 ng/ mL CXCL9 did not alter the AKT signaling pathway in any of our four cell lines. In contrast, after 15 and 30 minute exposures to 100 ng/mL CXCL9, ERK1/2 phosphorylation was downregulated in MzChA-1 and TFK-1 cells and upregulated in CCLP-1 cells.
No alteration was observed in the ERK1/2 signaling pathway in
HuCCT-1 cells ( Figure 4E ).
| D ISCUSS I ON
Chemokines are inextricably linked with cancers. and of elevated cancer grades. 16, 17 In addition, CXCR3A is a dominant participant in the exacerbation of tumor migration and invasion abilities, via ERK1/2 activation and its cognate downstream pathways, in gastric and liver cancer cells. 15, 16 CXCR3A is involved in motility and invasion abilities; CXCR3B overexpression reduces these abilities in prostate cancer. 17 In the current study, we used cell lines that represented four human CCA subtypes. CCLP-1 is the most malignant cell line with epithelial-mesenchymal transformation traits. HuCCT-1 is a metastatic, moderately differentiated cell line. MzChA-1 is a metastatic, highly differentiated cell line. TFK-1 is a primary, papillary cell line. [22] [23] [24] [25] Our data indicated that upregulation of the CXCR3A-to-CXCR3B ratio was accompanied by elevated CCA tumor grading and enhanced tumor growth and invasion abilities via ERK1/2 signaling.
Manipulating TIME through positive modulation of CXCL9 release is a promising immunotherapeutic approach. 12 Cytotoxic chemotherapies, molecular targeted therapies and cytokine therapies have shown potential in upregulating CXCL9 release.
35,36
Hannesdóttir et al 35 isoform, is deemed oncogenic; it has contributed to immune evasion in many types of cancer. 40 Indeed, previous reports demonstrated that COX-2 inhibitors induced cell growth inhibition through cell cycle arrest and apoptosis in CCA. 41, 42 Notably, our preliminary data showed that low-dose celecoxib, a COX-2 selective inhibitor, significantly enhanced CXCL9 release in all CXCL9-expressing CCA cell lines (data not shown); however, in vivo testing is needed to demonstrate the effectiveness of low-dose celecoxib in iCCA. Moreover, further investigation could provide effective drugs that have the potential to alter TIME via upregulation of endogenous CXCL9 in iCCA.
The current study has several limitations. First, we used single-labelling IHC staining for the detection of a certain subset of tumor-infiltrating immune cells in iCCA tissues. However, each primary Ab used for analysis could stain multiple subsets of immune cells. Second, we did not investigate which types of immune cells were predominantly involved in IFN-γ production. As endogenous CXCL9 can be released in the presence of immune cell-derived IFN-γ, clarifying this point is of great importance to better understand the impact of CXCL9 on TIME in iCCA. Third, in this study, we did not clarify the extent to which the different CXCR3 isoforms contributed to cell growth and invasion abilities induced by CXCL9, nor did we examine the downstream of the ERK1/2 signaling pathway, which might alter tumor behaviors. However, importantly, we showed that CXCL9 was unlikely to exacerbate tumor aggressiveness in CXCL9-expressing CCA.
In conclusion, we showed that CXCL9 had prognostic significance in iCCA, and that it was correlated with tumor-infiltrating NK cells. Our results also suggested that upregulation of CXCL9 is a promising therapeutic approach by inducing immunopotentiation without promoting tumor aggressiveness in patients with CXCL9-expressing iCCA.
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